Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update On FDA-Approved Expanded Access Program For A US Breast Cancer Patient; Says Patient Remains Cancer Free and Has Reported No Significant Safety Or Tolerability Issues Over Course Of Treatment
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics announced a positive five-year update on its FDA-approved Expanded Access Program for a US breast cancer patient using (Z)-Endoxifen. The patient remains cancer-free with no significant safety or tolerability issues reported.
March 19, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atossa Therapeutics' positive five-year update on (Z)-Endoxifen treatment for breast cancer could boost investor confidence and potentially impact stock positively.
Positive clinical updates, especially those related to cancer treatment, tend to have a favorable impact on biotech companies' stock prices. Given the significance of a five-year cancer-free update, this news could positively influence Atossa Therapeutics' stock in the short term by boosting investor confidence in the company's pipeline and its potential for successful treatments.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100